S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:PODD

Insulet Stock Forecast, Price & News

$295.39
-2.17 (-0.73%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$294.02
$303.46
50-Day Range
$276.54
$318.29
52-Week Range
$218.28
$324.81
Volume
178,809 shs
Average Volume
426,854 shs
Market Capitalization
$20.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.66
30 days | 90 days | 365 days | Advanced Chart
Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.


Insulet logo

About Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Headlines

Insulet to Present at Nasdaq’s 45th Investor Conference
November 24, 2021 |  finance.yahoo.com
Insulet (NASDAQ:PODD) Hits New 1-Year High at $324.81
November 10, 2021 |  americanbankingnews.com
Raymond James Boosts Insulet (NASDAQ:PODD) Price Target to $329.00
November 8, 2021 |  americanbankingnews.com
Reviewing Insulet (NASDAQ:PODD) & Pulse Biosciences (NASDAQ:PLSE)
November 5, 2021 |  americanbankingnews.com
Insulet (NASDAQ:PODD) PT Raised to $350.00
November 5, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
1,900
Year Founded
2000

Sales & Book Value

Annual Sales
$904.40 million
Cash Flow
$0.89 per share
Book Value
$7.22 per share

Profitability

Net Income
$6.80 million
Pretax Margin
-3.03%

Debt

Price-To-Earnings

Miscellaneous

Free Float
68,277,000
Market Cap
$20.37 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

Social Links


MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

682nd out of 1,391 stocks

Surgical & Medical Instruments Industry

74th out of 125 stocks

Analyst Opinion: 2.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -












Insulet (NASDAQ:PODD) Frequently Asked Questions

Is Insulet a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Insulet stock.
View analyst ratings for Insulet
or view top-rated stocks.

How has Insulet's stock been impacted by COVID-19 (Coronavirus)?

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PODD stock has increased by 71.6% and is now trading at $295.39.
View which stocks have been most impacted by COVID-19
.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) issued its earnings results on Thursday, November, 4th. The medical instruments supplier reported $0.18 earnings per share for the quarter, missing the consensus estimate of $0.25 by $0.07. The medical instruments supplier earned $275.60 million during the quarter, compared to analyst estimates of $272.62 million. Insulet had a positive trailing twelve-month return on equity of 0.63% and a negative net margin of 2.84%. The firm's quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 EPS.
View Insulet's earnings history
.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.07 billion-$1.09 billion, compared to the consensus revenue estimate of $1.08 billion.

What price target have analysts set for PODD?

12 analysts have issued 12-month price targets for Insulet's shares. Their forecasts range from $268.00 to $350.00. On average, they anticipate Insulet's stock price to reach $311.20 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Shacey Petrovic, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Charles Alpuche, Chief Operations Officer & Executive VP (LinkedIn Profile)
  • Wayde Dwight McMillan, Chief Financial Officer, Treasurer & Executive VP
  • Trang Ly, Senior Vice President & Medical Director
  • Michael P. Spears, Senior VP-Quality, Regulatory Affairs & Compliance

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (10.49%), Capital World Investors (10.25%), Primecap Management Co. CA (1.99%), Viking Global Investors LP (1.47%), Geode Capital Management LLC (1.26%) and Janus Henderson Group PLC (1.24%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet
.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, KBC Group NV, Lord Abbett & CO. LLC, Eagle Asset Management Inc., Primecap Management Co. CA, Capital World Investors, Principal Financial Group Inc., and Cubist Systematic Strategies LLC. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, John A Fallon, Sally Crawford, and Shacey Petrovic.
View insider buying and selling activity for Insulet
or view top insider-selling stocks.

Which institutional investors are buying Insulet stock?

PODD stock was purchased by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Capital Research Global Investors, Janus Henderson Group PLC, Frontier Capital Management Co. LLC, Bellevue Group AG, Bank of New York Mellon Corp, Geode Capital Management LLC, and Achmea Investment Management B.V..
View insider buying and selling activity for Insulet
or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $295.39.

How much money does Insulet make?

Insulet has a market capitalization of $20.37 billion and generates $904.40 million in revenue each year. The medical instruments supplier earns $6.80 million in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 1,900 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

Where are Insulet's headquarters?

Insulet is headquartered at 100 NAGOG PARK, ACTON MA, 01720.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at [email protected], or via fax at 978-600-0120.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.